The 158VV Fcgamma receptor 3A genotype is associated with response to rituximab in rheumatoid arthritis: Results of an italian multicentre study

Luca Quartuccio, Martina Fabris, Elena Pontarini, Sara Salvin, Alen Zabotti, Maurizio Benucci, Mariangela Manfredi, Domenico Biasi, Viviana Ravagnani, Fabiola Atzeni, Piercarlo Sarzi-Puttini, Pia Morassi, Fabio Fischetti, Paola Tomietto, Laura Bazzichi, Marta Saracco, Raffaele Pellerito, Marco Cimmino, Franco Schiavon, Valeria CarraroAngelo Semeraro, Roberto Caporali, Lorenzo Cavagna, Roberto Bortolotti, Giuseppe Paolazzi, Marcello Govoni, Stefano Bombardieri, Salvatore De Vita

Research output: Contribution to journalArticle

Abstract

Objective: The polymorphism 158V/F of Fc fragment of IgG (FCGR) type 3A may influence the response to rituximab (RTX) in rheumatoid arthritis (RA). We investigated the FCG3A polymorphism in a large cohort of RA patients treated with RTX, also by considering the possible loss of response from month +4 to +6 after RTX and the presence of established predictors of response. Methods: The study analysed 212 RA patients. European League Against Rheumatism (EULAR) response was evaluated at months +4 and +6 after the first RTX infusion. The FCGR3A polymorphism was analysed by PCR followed by Sanger sequencing. Results: The FCGR3A genotypes were associated with EULAR response (good or moderate) at month +6 (response in 34/38 (89.5%) VV vs 70/106 (66%) VF and in 51/77 (66.2%) FF patients; p=0.01), but not at month +4 (response in 32/37 (86.5%) VV vs 69/102 (67.6%) VF and 53/73 (72.6%) FF patients; p=0.09). Loss of response was observed only in VF and FF carriers ((VV vs VF vs FF: 0/37 (0%) vs 11/102 (10.8%) vs 12/73 (16.4%); p=0.02)). Probability of response at month +6 was very high when at least two of the three following items selected by multivariate analysis were present: positive rheumatoid factor and/or anticyclic citrullinated peptide antibodies, previous treatment with ≤1 anti-tumor necrosis factor (TNF) agent, and 158VV FCGR3A genotype (p

Original languageEnglish
Pages (from-to)716-721
Number of pages6
JournalAnnals of the Rheumatic Diseases
Volume73
Issue number4
DOIs
Publication statusPublished - 2014

ASJC Scopus subject areas

  • Rheumatology
  • Immunology
  • Biochemistry, Genetics and Molecular Biology(all)
  • Immunology and Allergy

Fingerprint Dive into the research topics of 'The 158VV Fcgamma receptor 3A genotype is associated with response to rituximab in rheumatoid arthritis: Results of an italian multicentre study'. Together they form a unique fingerprint.

  • Cite this

    Quartuccio, L., Fabris, M., Pontarini, E., Salvin, S., Zabotti, A., Benucci, M., Manfredi, M., Biasi, D., Ravagnani, V., Atzeni, F., Sarzi-Puttini, P., Morassi, P., Fischetti, F., Tomietto, P., Bazzichi, L., Saracco, M., Pellerito, R., Cimmino, M., Schiavon, F., ... De Vita, S. (2014). The 158VV Fcgamma receptor 3A genotype is associated with response to rituximab in rheumatoid arthritis: Results of an italian multicentre study. Annals of the Rheumatic Diseases, 73(4), 716-721. https://doi.org/10.1136/annrheumdis-2012-202435